Kimi.Bo

KIMI.BO has a liquidity risk profile that is currently rated as medium, with a debt-to-equity ratio of 3.95 and a current ratio of 0.92, indicating that the company's short-term liabilities exceed its short-term assets. The company's free cash flow of INR 83.92 million provides some buffer, but its operating cash flow of INR 213.14 million is insufficient to cover its long-term debt of INR 393.58 million. The negative net cash position further exacerbates the liquidity risk.

In terms of profitability, KIMI.BO reports a return on equity (ROE) of 96.45% and a return on assets (ROA) of 8.64%, which are strong indicators of efficient capital use and asset management. However, these figures should be compared to the industry median to determine whether they are above or below average. The company's net income of INR 96.12 million and operating income of INR 168.71 million suggest a healthy margin, but the gross profit of INR 421.38 million indicates that cost control remains a challenge.

KIMI.BO's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks, particularly in the pharmaceutical sector where regulatory and pricing pressures can vary significantly by region. The absence of segmental or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.

The company's growth trajectory is not clearly defined in the available data. While the current fiscal year's revenue of INR 1.19 billion provides a baseline, there is no disclosed outlook for the next fiscal year. The capital expenditure of INR -45.99 million suggests a reduction in investment, which could indicate a strategic shift or financial constraints. The absence of a forward-looking revenue growth rate makes it difficult to assess the company's long-term growth potential.

KIMI.BO's risk assessment highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of equity dilution. However, the negative net cash position and high debt-to-equity ratio suggest that the company may need to raise additional capital in the future, which could lead to dilution. The risk assessment does not identify any specific regulatory or geopolitical risks, but the pharmaceutical industry is inherently subject to regulatory changes and pricing pressures.

Recent events related to KIMI.BO are not disclosed in the available data. The company's financial statements do not include any recent filings or transcripts that would provide insight into management's strategy or operational performance. The absence of recent events makes it difficult to assess the company's current position in the market and its ability to respond to industry challenges.